loader image

Fold the future

At Sibylla Biotech, we face the complexity of drug discovery with the power of an innovative computational approach to tackle unmet medical needs.

Sibylla’s platform leverages on the enabling breakthrough of simulating protein folding pathways to unveil a new class of small-molecule degraders. Such compounds trigger the degradation of the target protein by interfering with its folding pathway.

By exploiting this new paradigm that we named “Pharmacological Protein Inactivation by Folding Intermediates Targeting” (PPI-FIT), Sibylla can identify and develop small molecules acting on targets involved in different types of diseases. Indeed, PPI-FIT is applicable to any therapeutic area.

Sibylla’s biology lab test and characterize folding interfering degraders. Promising compounds are then optimized and developed by relying on structure-based and ligand-based rational drug design approaches.

 

 

 

PPI-FIT

Computational platform

Early stage drug discovery

Sibylla Biotech Appoints Dominique Bridon as Executive Chairman of the Board

Sibylla Biotech Appoints Dominique Bridon as Executive Chairman of the Board Milan, Italy, September 28, 2023 – Sibylla Biotech today announces the appointment of Dominique Bridon, Ph.D., as Executive Chairman of its Board of Directors. Dr. Bridon brings more than 30...

Sibylla Biotech Raises €23 Million Series A to Advance Protein Degradation by Folding Interference Pipeline and Expand Technology Platform

Sibylla Biotech Raises €23 Million Series A to Advance Protein Degradation by Folding Interference Pipeline and Expand Technology Platform Verona, Italy, October 4, 2022 – Sibylla Biotech today announced the successful close of its €23 million Series A financing round...

New team member! – Leda Bencheva

Leda Bencheva hired as Principal Scientist in Medicinal Chemistry Lab

Giovanni Spagnolli appointed as CTO

Giovanni Spagnolli appointed as CTO of Sibylla Biotech

New team member! – Alexandros Patsilinakos

Alexandros Patsilinakos hired as Head of Medicinal Chemistry Lab

Sibylla Biotech selected by Nature among the eight best start-ups in the world in the life-science sector

Sibylla Biotech selected by Nature among the eight best start-ups in the world in the life-science sector Sibylla Biotech, a spin-off of INFN, the University of Trento, and the University of Perugia, has been selected, the only Italian company, as a finalist of the...

Sibylla Biotech Announces Drug Discovery Agreement with Takeda

Sibylla Biotech will use its Drug Discovery platform to modulate the activity of targets supplied by Takeda. The Italian startup company will partner its innovative PPI-FIT Drug Discovery platform with Takeda to generate novel compounds designed to modulate the...

The scientific paper about PPI-FIT technology

Recent computational advancements in the simulation of biochemical processes allow investigating the mechanisms involved in protein regulation with realistic physics-based models, at an atomistic level of resolution.

New team member! – Serena Bonifati

Serena Bonifati hired in the scientific staff

New structural target against COVID-19

A new structural target for drug development against COVID-19 has been unveiled today by Sibylla Biotech in collaboration with the Italian National Institute of Nuclear Physics (INFN), the University of Trento and University of Perugia.